Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
F-Prime Capital
AddedFeb 13, 2024
UpdatedJul 22, 2026
F-Prime Capital

F-Prime Capital

Operating

F-Prime Capital: A global healthcare and technology firm investing in life-improving solutions.

Location
Cambridge, MA, US
Founded
1946
Firm
Compare
Portfolio
Employees
News
Website

Investments

Comanche Biopharma
Comanche Biopharma

Total Raised

$111.1M

Rounds

2

Series B$75MJanuary 2024
Series A$36.1MMay 2023
Dispatch
Dispatch

Total Raised

$14.9M

Rounds

3

Seed$8MJanuary 2024
Burro
Burro
Series B

Total Raised

$36.6M

Rounds

7

Series B$24MJanuary 2024
OnCusp Therapeutics
OnCusp Therapeutics

Total Raised

$125M

Rounds

2

Series A$100MJanuary 2024
Devoted Health
Devoted Health

Total Raised

$2.1B

Rounds

6

Series E$175MDecember 2023
Shinobi Therapeutics
Shinobi Therapeutics

Total Raised

$51M

Rounds

1

Series A$51MDecember 2023
Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
Artbio
Artbio

Total Raised

$113M

Rounds

2

Series A$90MDecember 2023
Seed$23MJune 2023
Eleos Health
Eleos Health
Series B

Total Raised

$68M

Rounds

5

Series B$40MNovember 2023
Warmly
Warmly

Total Raised

$15.9M

Rounds

7

Series A$11MOctober 2023
Doceree
Doceree

Total Raised

$47M

Rounds

5

Series B$35MSeptember 2023
Avalyn Pharma
Avalyn Pharma

Total Raised

$272.5M

Rounds

3

Series C$175MSeptember 2023
Adela
Adela

Total Raised

$108M

Rounds

2

Series A$48MSeptember 2023
Nvelop Therapeutics
Nvelop Therapeutics

Total Raised

$100M

Rounds

1

Seed$100MSeptember 2023
Better Life Partners
Better Life Partners

Total Raised

$38.3M

Rounds

4

Series B$26.5MAugust 2023
Simon Data
Simon Data

Total Raised

$115.8M

Rounds

6

Series D$54MAugust 2023
K36 Therapeutics
K36 Therapeutics

Total Raised

$100M

Rounds

2

Series B$70MJune 2023
Albert Invent
Albert Invent

Total Raised

$7.5M

Rounds

1

Seed$7.5MJune 2023
Axoni
Axoni
Acquired

Total Raised

$109.8M

Rounds

5

Series Unknown$20MApril 2023
Adcentrx Therapeutics
Adcentrx Therapeutics

Total Raised

$101M

Rounds

2

Series A$51MApril 2023
Tradier
Tradier

Total Raised

$30.7M

Rounds

4

Series B$24.6MApril 2023
1upHealth
1upHealth

Total Raised

$75.5M

Rounds

5

Series C$40MApril 2023
SpectrumAi
SpectrumAi

Total Raised

$29M

Rounds

3

Series A$20MMarch 2023